Sanofi response to the situation in Ukraine

Update as of March 23

We continue to be shocked and saddened by the terrible brutality of the Russian aggression against Ukraine and the resulting suffering of the Ukrainian people. This is an enormous tragedy, and we continue to consider how we can best help the people of Ukraine. 

We want to share an update on our company’s response to date

As a purpose-driven organization working in the field of healthcare, we continue securing access to essential medicines and vaccines for patients.

We stand in opposition to the Russian war in Ukraine and in full support of the position of the international community, we have decided to stop immediately any new spending not related to the supply of our essential and life-changing medicines and vaccines in Russia, as well as in Belarus.

This includes all advertising and promotional spending and a halt to any new recruitment of patients for ongoing clinical trials, though we will continue to treat patients already enrolled.

A complete cessation of our activities would deprive people of the essential and life-changing medicines and vaccines they need and add to suffering. This would contradict our purpose. We will stay focused on patients, as we always have. 

We are doing everything we can to support Ukraine and the Ukrainian people, starting with our own colleagues. A set of exceptional measures were taken last week to help our employees in Ukraine face this critical situation. We are also providing specific support through our teams in neighboring countries to colleagues and their families who have made the difficult decision to leave Ukraine.

In addition to our company’s financial donations to the Red Cross, our Sanofi Foundation is coordinating and accelerating the donations of essential medicines and vaccines to support Ukrainian patients and Ukrainian refugees. As of today, 10.5 million daily treatments (e.g., insulins, anti-epileptics and medicines used in emergency situations) have been donated, potentially benefitting 360,000 patients.

We continue to hope that a resolution to this crisis will be found as soon as possible. We will continue to play our part in supporting our own colleagues in Ukraine, as well as the Ukrainian people and patients, for as long as it will be needed. 

We are actively working on solutions to enable continued access to treatment for all our Ukrainian patients in and outside of Ukraine:

  • For patients participating in a clinical trial with a Sanofi product:  If you have questions about your study participation, please contact us at +441223777070.  We can respond either in English or in Ukrainian. 
  • For all other questions about Sanofi products, please contact Sanofi Medical Information in the country you are located in.  Alternatively, you can send your question to